期刊
ENDOCRINE REVIEWS
卷 38, 期 2, 页码 145-168出版社
ENDOCRINE SOC
DOI: 10.1210/er.2016-1122
关键词
-
资金
- National Institutes of Health [HL115141, HL117994, HL134849, GM115605]
- Arthur K. Watson Charitable Trust
- Dr. Ralph and Marian Falk Medical Research Trust
- American Heart Association (SDG) [15SDG25400012]
- Boston Nutrition Obesity Research Center Pilot and Feasibility award under National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [P30KD046200]
- Watkins Discovery Award
- American Diabetes Association [1-16-JDF-046]
Chronic, low-grade systemic inflammation and impaired microvascular function are critical hallmarks in the development of insulin resistance. Accordingly, insulin resistance is a major risk factor for type 2 diabetes and cardiovascular disease. Accumulating studies demonstrate that restoration of impaired function of the diabetic macro-and microvasculature may ameliorate a range of cardiovascular disease states and diabetes-associated complications. In this review, we focus on the emerging role of microRNAs (miRNAs), noncoding RNAs that finetune target gene expression and signaling pathways, in insulin-responsive tissues and cell types important for maintaining optimal vascular homeostasis and preventing the sequelae of diabetes-induced end organ injury. We highlight current pathophysiological paradigms of miRNAs and their targets involved in regulating the diabetic microvasculature in a range of diabetes-associated complications such as retinopathy, nephropathy, wound healing, and myocardial injury. Weprovide an update of the potential use of circulatingmiRNAs diagnostically in type I or type II diabetes. Finally, we discuss emerging delivery platforms for manipulating miRNA expression or function as the next frontier in therapeutic intervention to improve diabetes-associated microvascular dysfunction and its attendant clinical consequences.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据